Expand JAZZ Menu
JAZZ MENU

JAZZ Latest Press Releases

-- June 17, 2026 --

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies Business Wire 7:00 AM

-- June 16, 2026 --

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia PRNewswire 4:05 PM

-- June 12, 2026 --

Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer PRNewswire 8:00 AM

-- June 4, 2026 --

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia PRNewswire 7:45 AM

-- May 27, 2026 --

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PRNewswire 5:00 PM

-- May 12, 2026 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PRNewswire 4:15 PM

-- May 5, 2026 --

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results PRNewswire 4:05 PM

-- April 27, 2026 --

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PRNewswire 7:45 AM

-- April 21, 2026 --

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 PRNewswire 4:15 PM
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca (lurbinectedin) PRNewswire 4:05 PM

-- April 9, 2026 --

Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting PRNewswire 7:45 AM

-- April 1, 2026 --

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference PRNewswire 4:15 PM

-- March 24, 2026 --

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education PRNewswire 1:50 PM

-- March 18, 2026 --

Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 PRNewswire 7:44 AM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 24, 2026 --

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PRNewswire 4:05 PM

-- February 17, 2026 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PRNewswire 4:15 PM

-- February 10, 2026 --

Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PRNewswire 4:15 PM
Market Data Delayed 15 Minutes